Losartan

Losartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for COZAAR tablets (losartan potassium), lists three uses: treating high blood pressure in adults and children, reducing the risk of stroke in patients with high blood pressure and left ventricular hypertrophy (the label says this benefit does not apply to Black patients), and treating diabetic nephropathy in patients with type 2 diabetes and a history of high blood pressure. Cozaar is the brand name on the label read.

Also called Cozaar · Losartan potassium

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 52175; UNII 3ST302B24A. The label names the substance as losartan potassium, so UNII 3ST302B24A is the UNII of the potassium salt and is a broad match. MeSH descriptor D019808 is Losartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Organon LLC label for COZAAR (losartan potassium) tablets, application NDA020386, effective 2026-01-20 in openFDA; Drugs@FDA lists the application's sponsor as ORGANON. Other losartan labels, including generic products and fixed combinations with hydrochlorothiazide, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 21 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
21
Phase 3 or 4
14
Recruiting
2
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingActive, not recruitingCompletedTerminatedUnknown statusAll statuses
Phase 2005027
Phase 31171010
Phase 4102014
All phases21141321

Conditions these trials study

And 7 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 14 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII 3ST302B24A

Claims and evidence

Context Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)

Recipient
Child
Population
Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Label wording: children greater than 6 years old (highlights wording)
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Children with hypertension (children greater than 6 years old (highlights wording))
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children greater than 6 years old (the highlights wording; a later section of the same label says pediatric patients 6 years of age and older).

    Applies to Child Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260120.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children); the stroke and diabetic nephropathy indications do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults for hypertension, as the passage read states; not stated for the other indications
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients with hypertension
  • Patients with hypertension and left ventricular hypertrophy (the label says the stroke benefit does not apply to Black patients)
  • Patients with type 2 diabetes, a history of hypertension, nephropathy, an elevated serum creatinine and proteinuria
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

    Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260120.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application NDA020386 (COZAAR, sponsor ORGANON): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA020386, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA020386, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      e0ad0edb3a20d7283469925ea923a9d98524b4ca8f423e4915a9465c019d4abc
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children greater than 6 years old (the highlights wording; a later section of the same label says pediatric patients 6 years of age and older).

    Applies to Child Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)

    Population, setting and follow-up
    • Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Label wording: children greater than 6 years old (highlights wording)
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260120.
      Retrieved
      Source effective date
      2026-01-20
      Source state
      Current
      Version fingerprint
      536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ARBLI

No label from the application holder was found in the openFDA label dataset for application NDA218772. This page does not show another labeler's label in its place.

COZAAR

No label from the application holder was found in the openFDA label dataset for application NDA020386. This page does not show another labeler's label in its place.

HYZAAR

No label from the application holder was found in the openFDA label dataset for application NDA020387. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020386 COZAAR
  2. Approval NDA020387 HYZAAR
  3. Supplemental approval NDA020386 COZAAR
  4. Supplemental approval NDA020386 COZAAR
  5. Supplemental approval NDA020386 COZAAR
  6. Supplemental approval NDA020387 HYZAAR
  7. Supplemental approval NDA020386 COZAAR
  8. Supplemental approval NDA020387 HYZAAR
  9. Supplemental approval NDA020387 HYZAAR
  10. Approval NDA218772 ARBLI

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 3

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA020386

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA020387

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA218772

Registry trials 21

Record details

Record id
cardio:losartan
Content hash
e55023eb6ea78a13524e29bcb5f36174bb803fbd91fd4b872421f1285ee5537f